What was the market valuation of the US metastases spinal-tumor market in 2024?

The market valuation was $884.24 Million in 2024. Read More

What is the projected market valuation for the US metastases spinal-tumor market by 2035?

The projected valuation for 2035 is $1406.55 Million. Read More

What is the expected CAGR for the US metastases spinal-tumor market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period is 4.31%. Read More

Which treatment type segment had the highest valuation in 2024?

The Targeted Therapy segment had the highest valuation at $250.0 Million in 2024. Read More

What are the projected valuations for the Immunotherapy segment by 2035?

The projected valuation for the Immunotherapy segment is $446.55 Million by 2035. Read More

Which end user segment contributed the most to the market in 2024?

The Hospitals segment contributed the most with a valuation of $400.0 Million in 2024. Read More

What is the projected valuation for Ambulatory Surgical Centers by 2035?

The projected valuation for Ambulatory Surgical Centers is $450.0 Million by 2035. Read More

Which cancer type segment had a valuation of $250.0 Million in 2024?

The Lung Cancer segment had a valuation of $250.0 Million in 2024. Read More

What is the projected valuation for the Intravenous route of administration by 2035?

The projected valuation for the Intravenous route of administration is $800.0 Million by 2035. Read More

Who are the key players in the US metastases spinal-tumor market?

Key players include Medtronic, Stryker, Johnson & Johnson, Baxter International, Boston Scientific, NuVasive, Zimmer Biomet, and Abbott Laboratories. Read More

US Metastases Spinal Tumor Market

US Metastatic Spinal Tumor Market Research Report By Treatment Type (Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Kidney Cancer) and By Route of Administration (Oral, Intravenous, Intrathecal) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.31%

2024 Market Size

$ 884.24 Million

2035 Market Size

$ 1,406.55 Million

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/18433-HCR | Pages: 100 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Treatment Type (USD Million)
  1. 4.1.1 Radiation Therapy
  2. 4.1.2 Chemotherapy
  3. 4.1.3 Targeted Therapy
  4. 4.1.4 Immunotherapy
2. 4.2 Construction, BY End User (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Ambulatory Surgical Centers
  3. 4.2.3 Specialty Clinics
3. 4.3 Construction, BY Cancer Type (USD Million)
  1. 4.3.1 Breast Cancer
  2. 4.3.2 Lung Cancer
  3. 4.3.3 Prostate Cancer
  4. 4.3.4 Kidney Cancer
4. 4.4 Construction, BY Route of Administration (USD Million)
  1. 4.4.1 Oral
  2. 4.4.2 Intravenous
  3. 4.4.3 Intrathecal
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Medtronic (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Stryker (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Baxter International (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boston Scientific (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 NuVasive (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Zimmer Biomet (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Abbott Laboratories (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TREATMENT TYPE
3. 6.3 US MARKET ANALYSIS BY END USER
4. 6.4 US MARKET ANALYSIS BY CANCER TYPE
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TREATMENT TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY END USER, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY END USER, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY CANCER TYPE, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY CANCER TYPE, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY END USER, 2025-2035 (USD Million)
  3. 7.2.3 BY CANCER TYPE, 2025-2035 (USD Million)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Metastases Spinal Tumor Market Segmentation

US Metastases Spinal Tumor Market By Treatment Type (USD Million, 2025-2035)

Radiation Therapy
Chemotherapy
Targeted Therapy
Immunotherapy

US Metastases Spinal Tumor Market By End User (USD Million, 2025-2035)

Hospitals
Ambulatory Surgical Centers
Specialty Clinics

US Metastases Spinal Tumor Market By Cancer Type (USD Million, 2025-2035)

Breast Cancer
Lung Cancer
Prostate Cancer
Kidney Cancer

US Metastases Spinal Tumor Market By Route of Administration (USD Million, 2025-2035)

Oral
Intravenous
Intrathecal

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”